SCHEMBL1033197

SCHEMBL1033197

COc1ccc(Cl)cc1-c1ccnc(Cl)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 2/20 0.55
AGPAT2 O15120 11/20 0.49
JAK2 O60674 1/20 0.46
HPGD P15428 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
RECQL P46063 1/20 0.45
USP2 O75604 1/20 0.43
PRNP P04156 1/20 0.43
PPARG P37231 1/20 0.43
MAPK10 P53779 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HSD17B10 Q99714 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
TNF P01375 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31011561 0.86 AGPAT2 (0.42) ALDH1A1KDM4EAGPAT2HPGDMEN1
SCHEMBL3624500 0.86 AGPAT2 (0.42) ALDH1A1KDM4EAGPAT2HPGDMEN1
SCHEMBL3625797 0.86 CDK9 (0.44) ALDH1A1KDM4EUSP2
SCHEMBL1033206 0.82 LMNA (0.53) ALDH1A1KDM4EAGPAT2JAK2HPGD
SCHEMBL3625411 0.81 IDO1 (0.45) ALDH1A1KDM4E
SCHEMBL3399379 0.81 ALDH1A1 (0.51) ALDH1A1KDM4EAGPAT2HPGDMEN1
SCHEMBL2983938 0.81 HSP90AA1 (0.51) ALDH1A1KDM4EHPGDSMN1; SMN2USP2
SCHEMBL31505996 0.81 HSP90AA1 (0.51) ALDH1A1KDM4EHPGDSMN1; SMN2USP2
SCHEMBL1033005 0.80 KDM4E (0.48) ALDH1A1KDM4EAGPAT2JAK2HPGD
SCHEMBL31011660 0.80 PDGFRB (0.41) ALDH1A1KDM4EHPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO disclosed
WO-2010151747-A1 PYRIMINE COMPOUNDS AND METHODS OF MAKING AND USING SAME CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2010-12-29 WO disclosed
WO-2010015653-A1 PYRIMIDINE DERIVATIVES AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE SMITHKLINE BEECHAM CORPORATION (US) 2010-02-11 WO disclosed